Abstract

Introduction. PriMatrix (TEI Biosciences Inc., Boston, MA, USA) is a novel acellular collagen matrix derived from fetal bovine dermis that is designed for use in partial- and full-thickness wounds. This study analyzes the cellular response to PriMatrix in vivo, as well as the ability of this matrix to facilitate normal tissue regeneration. Methods. Five by five mm squares of rehydrated PriMatrix were implanted in a subcutaneous fashion on the dorsum of wild-type mice. Implant site tissue was harvested for histology, immunohistochemistry (IHC), and flow cytometric analyses at multiple time points until day 28. Results. PriMatrix implants were found to go through a biological progression initiated by a transient infiltrate of inflammatory cells, followed by mesenchymal cell recruitment and vascular development. IHC analysis revealed that the majority of the implanted fetal dermal collagen fibers persisted through day 28 but underwent remodeling and cellular repopulation to form tissue with a density and morphology consistent with healthy dermis. Conclusions. PriMatrix implants undergo progressive in vivo remodeling, facilitating the regeneration of histologically normal tissue through a mild inflammatory and progenitor cell response. Regeneration of normal tissue is especially important in a wound environment, and these findings warrant further investigation of PriMatrix in this setting.

Highlights

  • PriMatrix (TEI Biosciences Inc., Boston, MA, USA) is a novel acellular collagen matrix derived from fetal bovine dermis that is designed for use in partial- and full-thickness wounds

  • PriMatrix is a novel acellular collagen matrix that is designed for use in partial- and full-thickness wounds

  • PriMatrix Extracellular matrices (ECMs) is produced from fetal bovine dermis, a rich source of type III collagen associated with wound healing and developing tissues [1, 4, 5], and is not denatured or artificially cross-linked during the manufacturing process [1]

Read more

Summary

Introduction

PriMatrix (TEI Biosciences Inc., Boston, MA, USA) is a novel acellular collagen matrix derived from fetal bovine dermis that is designed for use in partial- and full-thickness wounds. PriMatrix implants undergo progressive in vivo remodeling, facilitating the regeneration of histologically normal tissue through a mild inflammatory and progenitor cell response. PriMatrix ECM is produced from fetal bovine dermis, a rich source of type III collagen associated with wound healing and developing tissues [1, 4, 5], and is not denatured or artificially cross-linked during the manufacturing process [1]. SurgiMend (TEI Biosciences Inc., Boston, MA, USA), a fetal bovine derived ECM similar to PriMatrix but approved for hernia repair and reconstructive surgery applications, has previously demonstrated a desirable host integration and adaptation response for up to 15 months in a rat subcutaneous implant model [1]. A similar data and molecular characterization of the in vivo behavior of PriMatrix is lacking

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.